Abstract: The present invention belongs to the field of nucleotides and mRNA, and specifically relates to modified self-replicating mRNA. A polynucleotide fragment thereof comprises an integrated target fragment and one or more non-structural replicase domains from an ? virus, the integrated target fragment comprising a functional nucleotide analogue; and the functional nucleotide analogue comprises: at least one among pseudouridine, N1-methylpseudouridine, 5-hydroxymethoxycytidine, and N6-methyladenosine.

Abstract: The present invention provides PD-1 monoclonal antibodies, particularly human monoclonal antibodies of PD-1, which specifically bind to PD-1 with high affinity and comprise a heavy chain and a light chain. The present invention further provides nucleic acid sequence encoding the antibodies of the invention, cloning or expression vectors, host cells and methods for expressing or isolating the antibodies. Immunoconjugates, therapeutic compositions comprising the antibodies of the invention are also provided. The invention also provides methods for treating various cancers with anti-PD-1 antibodies.

Abstract: The present invention provides PD-1 monoclonal antibodies, particularly human monoclonal antibodies of PD-1, which specifically bind to PD-1 with high affinity and comprise a heavy chain and a light chain. The present invention further provides nucleic acid sequence encoding the antibodies of the invention, cloning or expression vectors, host cells and methods for expressing or isolating the antibodies. Immunoconjugates, therapeutic compositions comprising the antibodies of the invention are also provided. The invention also provides methods for treating various cancers with anti-PD-1 antibodies.

Abstract: The present invention provides PD-1 monoclonal antibodies, particularly human monoclonal antibodies of PD-1, which specifically bind to PD-1 with high affinity and comprise a heavy chain and a light chain. The present invention further provides nucleic acid sequence encoding the antibodies of the invention, cloning or expression vectors, host cells and methods for expressing or isolating the antibodies. Immunoconjugates, therapeutic compositions comprising the antibodies of the invention are also provided. The invention also provides methods for treating various cancers with anti-PD-1 antibodies.

Abstract: A terminal control method based on a fingerprint recognition key, a terminal control device based on a fingerprint recognition key, and a terminal are provided. The method includes: detecting a touch operation on the fingerprint recognition key, acquiring a touch parameter of the touch operation; and controlling a running state of a terminal, in a case where the touch parameter meets a preset condition. With the method, the terminal is controlled by the fingerprint recognition key to switch its running state, such as a turned-on state, a turned-off state, a sleep state, an awake state, a locked state, thereby simplify an operation and improving a user experience. In this case, the power key is cancelled since the function of the power key is implemented by the fingerprint recognition key, thereby reducing the physical components and thus the fabrication cost of the terminal.

Abstract: The present invention provides PD-1 monoclonal antibodies, particularly human monoclonal antibodies of PD-1, which specifically bind to PD-1 with high affinity and comprise a heavy chain and a light chain. The present invention further provides nucleic acid sequence encoding the antibodies of the invention, cloning or expression vectors, host cells and methods for expressing or isolating the antibodies. Immunoconjugates, therapeutic compositions comprising the antibodies of the invention are also provided. The invention also provides methods for treating various cancers with anti-PD-1 antibodies.

Abstract: A terminal control method based on a fingerprint recognition key, a terminal control device based on a fingerprint recognition key, and a terminal are provided. The method includes: detecting a touch operation on the fingerprint recognition key, acquiring a touch parameter of the touch operation; and controlling a running state of a terminal, in a case where the touch parameter meets a preset condition. With the method, the terminal is controlled by the fingerprint recognition key to switch its running state, such as a turned-on state, a turned-off state, a sleep state, an awake state, a locked state, thereby simplify an operation and improving a user experience. In this case, the power key is cancelled since the function of the power key is implemented by the fingerprint recognition key, thereby reducing the physical components and thus the fabrication cost of the terminal.

Abstract: Described herein is the use of phage display antibody engineering technology and synthetic peptide screening to identify SD1 and SD2, human single-domain antibodies to mesothelin. SD1 recognizes a conformational epitope at the C-terminal end (residues 539-588) of human mesothelin close to the cell surface. SD2 binds full-length mesothelin. To investigate SD1 as a potential therapeutic agent, a recombinant human Fc (SD1-hFc) fusion protein was generated. The SD1-hFc protein exhibits strong complement-dependent cytotoxicity (CDC), in addition to antibody-dependent cellular cytotoxicity (ADCC), against mesothelin-expressing tumor cells. Furthermore, the SD1-hFc protein causes significant tumor growth inhibition of tumor xenografts in nude mice. SD1 and SD2 are the first human single-domain antibodies targeting mesothelin-expressing tumors.

Abstract: Described herein is the use of phage display antibody engineering technology and synthetic peptide screening to identify SD1 and SD2, human single-domain antibodies to mesothelin. SD1 recognizes a conformational epitope at the C-terminal end (residues 539-588) of human mesothelin close to the cell surface. SD2 binds full-length mesothelin. To investigate SD1 as a potential therapeutic agent, a recombinant human Fc (SD1-hFc) fusion protein was generated. The SD1-hFc protein exhibits strong complement-dependent cytotoxicity (CDC), in addition to antibody-dependent cellular cytotoxicity (ADCC), against mesothelin-expressing tumor cells. Furthermore, the SD1-hFc protein causes significant tumor growth inhibition of tumor xenografts in nude mice. SD1 and SD2 are the first human single-domain antibodies targeting mesothelin-expressing tumors.